These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37053480)

  • 1. Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases-moving towards causal associations. Authors' reply.
    Chen J; Ruan X; Yuan S; Theodoratou E; Satsangi J; Li X
    Aliment Pharmacol Ther; 2023 May; 57(9):1048-1049. PubMed ID: 37053480
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases - moving towards causal associations.
    Geertsema S; van Goor H; Dijkstra G; Faber KN; Bourgonje AR
    Aliment Pharmacol Ther; 2023 May; 57(9):1046-1047. PubMed ID: 37053479
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: dermatological complications with therapy for inflammatory bowel disease--authors' reply.
    Ghosh S; Moran GW
    Aliment Pharmacol Ther; 2014 Jan; 39(2):233-4. PubMed ID: 24330245
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter: infliximab therapy for patients with inflammatory bowel disease--some unanswered questions. Authors' reply.
    Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
    Aliment Pharmacol Ther; 2015 Nov; 42(9):1134. PubMed ID: 26427756
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter: rationalising aminosalicylates in inflammatory bowel disease-authors' reply.
    Chapman TP; Frias Gomes C; Louis E; Colombel JF; Satsangi J
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1621. PubMed ID: 33085981
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease-authors' reply.
    Hadi Y; Kochhar GS
    Aliment Pharmacol Ther; 2022 Jul; 56(1):179. PubMed ID: 35689310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter: Antibiotics in gut dysbiosis and development of inflammatory bowel disease-More thought is needed-Authors' reply.
    Oh SJ; Kim HJ; Lee CK
    Aliment Pharmacol Ther; 2023 Oct; 58(8):840-841. PubMed ID: 37768283
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter: Thioguanine, an under-utilised option in inflammatory bowel disease? Authors' reply.
    Vasudevan A; Con D; van Langenberg DR
    Aliment Pharmacol Ther; 2024 Apr; 59(8):1011. PubMed ID: 38523135
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease-authors' reply.
    Vasudevan A; Con D; van Langenberg DR
    Aliment Pharmacol Ther; 2024 Mar; 59(6):794. PubMed ID: 38401137
    [No Abstract]   [Full Text] [Related]  

  • 10. Letter: Persisting with persistence-A caution as an outcome measure in inflammatory bowel disease: Authors' reply.
    Yiu TH; Ko Y; Pudipeddi A; Natale P; Leong RW
    Aliment Pharmacol Ther; 2024 Aug; 60(3):427-428. PubMed ID: 38922940
    [No Abstract]   [Full Text] [Related]  

  • 11. Letter: loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply.
    Mahmoud R; Schultheiss JPD; Fidder HH; Oldenburg B
    Aliment Pharmacol Ther; 2022 Feb; 55(4):499-500. PubMed ID: 35092052
    [No Abstract]   [Full Text] [Related]  

  • 12. Letter: predicting treatment discontinuation in inflammatory bowel disease-anti-TNF trough levels and anti-drug antibodies. Authors' reply.
    Roblin X; Nancey S; Paul S
    Aliment Pharmacol Ther; 2021 Aug; 54(4):538-539. PubMed ID: 34331805
    [No Abstract]   [Full Text] [Related]  

  • 13. Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply.
    Al-Ani AH; Prentice RE; Rentsch C; Christensen B
    Aliment Pharmacol Ther; 2021 Mar; 53(6):766-767. PubMed ID: 33599326
    [No Abstract]   [Full Text] [Related]  

  • 14. Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs-authors' reply.
    Khalili H; Casey K
    Aliment Pharmacol Ther; 2022 Apr; 55(7):884. PubMed ID: 35315105
    [No Abstract]   [Full Text] [Related]  

  • 15. Letter: rapid infliximab infusion is not always safe--authors' reply.
    Neef H; Adler J
    Aliment Pharmacol Ther; 2013 Oct; 38(7):844-5. PubMed ID: 24001100
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter: switches of 5-aminosalicylates in ulcerative colitis, risk of relapse and ascertainment bias--authors' reply.
    Robinson A; Hankins M; Wiseman G; Jones M
    Aliment Pharmacol Ther; 2014 Feb; 39(3):345-6. PubMed ID: 24397328
    [No Abstract]   [Full Text] [Related]  

  • 17. Letter: successful mercaptopurine therapy after azathioprine-related pancreatitis in patients with IBD - authors' reply.
    Hindorf U; Almer S
    Aliment Pharmacol Ther; 2013 Jan; 37(1):162-3. PubMed ID: 23205482
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis-a unique therapeutic target in inflammatory bowel disease. Authors' reply.
    Wang J; Goren I; Rieder F
    Aliment Pharmacol Ther; 2022 May; 55(10):1360. PubMed ID: 35472188
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial: progress towards more comprehensively understanding the sources of corticosteroids for patients with inflammatory bowel disease-authors' reply.
    Rosiou K; Selinger CP
    Aliment Pharmacol Ther; 2022 Sep; 56(5):898-899. PubMed ID: 35934863
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic. Authors' reply.
    Gisbert JP; Chaparro M
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1302-3. PubMed ID: 25968154
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.